Blog
RSS FeedPosted by Michael Wonder on 29 Apr 2024
Celltrion USA signs agreement with Express Scripts for its therapy for autoimmune diseases including the first FDA approved subcutaneous infliximab Zymfentra
28 April 2024 - Celltrion USA announced today that it has signed an agreement with Express Scripts, one of the nation's ...
Posted by Michael Wonder on 27 Apr 2024
Use evidence to support early coverage of gene therapy after accelerated approval
23 April 2024 - Gene editing and therapy to replace missing or defective genes is one of the most exciting ...
Posted by Michael Wonder on 22 Apr 2024
Alvotech signs US agreement to expand access for newly approved high concentration interchangeable biosimilar to Humira (adalimumab)
19 April 2024 - Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to ...
Posted by Michael Wonder on 18 Mar 2024
Zymfentra (infliximab-dyyb), the first and only FDA approved subcutaneous infliximab, now commercially available in the U.S.
17 March 2024 - Zymfentra is commercially available across the US on 15 March 2024. ...
Posted by Michael Wonder on 10 Jan 2024
AARP statement on FDA’s prescription drugs importation approval for Florida
8 January 2024 - AARP Executive Vice President and Chief Advocacy and Engagement Officer Nancy LeaMond issued the following statement ...
Posted by Michael Wonder on 05 Dec 2023
Zepbound (tirzepatide) is now available in US pharmacies for adults living with obesity
5 December 2023 - Express Scripts to add Zepbound to National Preferred Formulary. ...
Posted by Michael Wonder on 14 Nov 2023
Bayer provides update on Aliqopa (copanlisib)
14 November 2023 - Bayer today announced that, following discussions with the US FDA, it will work with the FDA on ...
Posted by Michael Wonder on 02 Nov 2023
HHS Secretary Becerra's statement on the FDA’s approval of Wezlana
31 October 2023 - Today, US Department of Health and Human Services Secretary Xavier Becerra released the following statement regarding ...
Posted by Michael Wonder on 03 Oct 2023
Adalimumab-adbm, Boehringer Ingelheim’s Interchangeable biosimilar to Humira, now available at low wholesale acquisition cost
2 October 2023 - Adalimumab-adbm will be priced at an 81% discount to Humira (adalimumab). ...
Posted by Michael Wonder on 21 Sep 2023
Supply and insurance issues snarl fall COVID-19 vaccine campaign for some
20 September 2023 - It has been just over a week since the US FDA and the US Centers for ...
Posted by Michael Wonder on 13 Sep 2023
First bladder cancer patient dosed with commercially available intravesical gene therapy Adstiladrin (nadofaragene firadenovec-vncg)
12 September 2023 - Ferring launches ABLE-41 Real World Evidence Study, a patient registry to explore early use, experiences and outcomes ...
Posted by Michael Wonder on 01 Sep 2023
Emergent BioSolutions’ Narcan nasal spray launches over the counter making it possible for everyone to help save a life from an opioid overdose emergency
30 August 2023 - Narcan nasal spray will be the first, life-saving emergency medicine for opioid overdose available on shelves beginning ...
Posted by Michael Wonder on 06 Aug 2023
Free the PrEP - over the counter access to HIV pre-exposure prophylaxis
5 August 2023 - Several barriers to access to preexposure prophylaxis for HIV could be alleviated by making it available over ...
Posted by Michael Wonder on 14 Jul 2023
TheracosBio announces commercial availability of Brenzavvy (bexagliflozin) for the treatment of adults with type 2 diabetes
13 July 2023 - Distribution through Mark Cuban Cost Plus Drug Company introduces affordably priced SGLT2 inhibitors. ...
Posted by Michael Wonder on 11 Jul 2023
Express Scripts adds three biosimilars to largest formulary to promote competition and advance affordability, choices for patients
11 July 2023 - Express Scripts will include Cyltezo and both Sandoz products (Hyrimoz and unbranded adalimumab-adaz) – inflammatory disease biosimilars ...